Navigation Links
Transport's Phase 2 Data Show Single Treatment SoloVir(TM) ETS Significantly Stops Progression of Cold Sore Episode
Date:11/28/2007

Data Presented Today at the 19th Annual Piper Jaffray Health Care

Conference

FRAMINGHAM, Mass. and NEW YORK, Nov. 28 /PRNewswire/ -- Today at the 19th Annual Piper Jaffray Health Care Conference, Dr. Dennis I. Goldberg, President and Chief Executive Officer of Transport Pharmaceuticals, Inc., presented compelling clinical results of a Phase 2 study designed to evaluate the safety and efficacy of the company's lead drug/device product, the SoloVir(TM) Electrokinetic Transdermal System (SoloVir(TM) ETS) for recurrent herpes labialis (cold sores). SoloVir(TM) ETS uses single-use drug cartridges containing Transport's novel, five-percent acyclovir gel.

This unique study was designed to determine the optimum treatment protocol based upon the immediate delivery of a large bolus of acyclovir into the skin during a herpetic episode, i.e. whether treatment at either the prodrome or erythema stage on day one of the herpetic episode was significantly better than placebo. TPI-H-221 was a multi center, randomized, double blind, placebo-controlled study that enrolled approximately 260 subjects.

Dennis I. Goldberg, President and CEO, commented on the clinical results, "The TPI-H-221 study has demonstrated that treatment at the erythema or papule/edema stages, the first visible signs of a cold sore, decreased the number of patients who progressed to classical lesions, and resulted in a dramatic decrease in healing times. Patients who treated earlier, at the prodrome stage, did not see a statistically significance benefit. Our Phase 2 study provides valuable insights into the treatment of herpes labialis. SoloVir(TM) ETS is the only one time treatment to achieve a statistically significant and clinically meaningful decrease in herpetic lesions. This study provides a number of important findings that provide a clear path for completing the development of this novel combination drug/device product."

Spotswood Sprua
'/>"/>

SOURCE Transport Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... CW4K was among those invited to ... and Partnership for a Healthier America (PHA) ... group's DrinkUP effort, which encourages people across ... , The seven organizations added included Brita®, First 5 ... Bottle, Santa Clara Valley Water District and The California ...
(Date:7/28/2014)... To commemorate World Hepatitis Day which ... Living with a Disability magazine has published a ... include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, short bowel ... article highlights that, in the context of receiving a ... other disabling conditions related to the digestive system must ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... Shore Points Capital announced today that it ... Inc., through a recapitalization of the Company led by ... investor in Loftware for over nine years, a period ... provider of enterprise level software solutions for supply chain ... for us, and we are proud of everything the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cuidado Casero ... and hospice, PCO, PCA, and PHC in Texas, New Mexico, ... a sponsor of the North Texas Chapter of PAM’s 2014 ... the Peruvian American Medical Society. The North Texas chapter was ... and other professionals interested in improving medical care for the ...
Breaking Medicine News(10 mins):Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2
... Peru, Jan. 14 The National Cancer Coalition ... announce a pilot program to assist cancer patients ... medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) ... Peruvian Health Ministry participated in a hand-over event ...
... to oust reformers, local union officers unopposedOAKLAND, Calif., ... Sal Rosselli and all 17 other statewide officers ... committee chair Debby Schneider. Their victory comes despite ... Stern to oust reformers in the local union ...
... Protections for Texas NursesAUSTIN, Texas, Jan. 14 ... hospitals will gain even more influence in setting appropriate ... The legislation, authored in the Senate by Sen. Jane ... Donna Howard (D-Austin), and supported by the Texas Nurses ...
... By the time they have been diagnosed with Alzheimer,s ... they cannot give informed consent to participate in research ... decision, but there is no clear policy for this ... increasingly common disease is often stalled. , But a ...
... Obesity continues to increase for women in the ... the ages of 35-44, there are approximately 3.3 million ... women who are obese. A new study published in ... there is an increased risk for midlife obesity among ...
... in French . , Montreal, January 14, 2009 ... progression of breast cancer. According to a recent study from ... in the Journal of Biological Chemistry , the protein ... the spread of tumours. Targeting this protein with drug therapy ...
Cached Medicine News:Health News:NCC and Wyeth Donation to Assist Cancer Patients in Latin America 2Health News:United Healthcare Workers Re-Elect All Statewide Officers 2Health News:Legislation Would Give Texas Nurses Even Stronger Voice in Hospital Staffing 2Health News:Legislation Would Give Texas Nurses Even Stronger Voice in Hospital Staffing 3Health News:Most support Alzheimer's research based on family consent 2Health News:Most support Alzheimer's research based on family consent 3Health News:Economic status affects obesity rates in Mexican-American and white women 2
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
(Date:7/25/2014)... CHICAGO, Ill., July 25, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... ended June 30, 2014. "This was another ... earnings per share above our original guidance and announced plans ...
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
... J. Ubl, president and CEO of the Advanced Medical Technology ... the House Ways and Means Committee of H.R. 436, the ... repeal the 2.3% excise tax on medical devices scheduled to ... Congress has taken the first step to stop the medical ...
... 31, 2012 The American Pharmacists Association (APhA), a ... profession of pharmacy, announced that on Monday evening, ... , was attacked and defaced by an unknown ... http://photos.prnewswire.com/prnh/20100820/APHALOGO-a ) APhA considers any ...
Cached Medicine Technology:
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
... Stent may become a practice-changing technology for ... treatment of lower urinary tract symptoms (LUTS). ... retention , Men unfit for surgery , ... therapy - TUMT, TUNA, Brachytherapy, Cryotherapy , ...
Medicine Products: